All In Biotech

Drug Trial Radar · NCT02080468

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Last checked: Nov 20, 2026Latest source record: Mar 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Feb 19, 2014

Primary completion

Apr 24, 2014

Study completion Apr 24, 2014

Sponsor

Lead sponsor
Aegerion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the effect of ethinyl estradiol (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and 2 primary metabolites, M1 and M3.

Conditions

  • Healthy

Interventions

  • lomitapideDrug

    20 mg

  • EE/norgestimateDrug

    1x0.035-mg EE/0.25-mg norgestimate tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
  2. Tmax for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
  3. AUC0-t for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
  4. AUC0-∞ for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing
  5. t1/2 for Arm 1 (Lomitapide & EE/Noregestimate - Taken Together)Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 169 hours after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit, Inc

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.